5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.86▲ | 0.87▼ | 0.87▼ | 0.89▼ | 0.91▼ |
MA10 | 0.86▼ | 0.86▼ | 0.87▼ | 0.88▲ | 0.95▼ |
MA20 | 0.87▼ | 0.86▼ | 0.86▼ | 0.90▼ | 1.04▼ |
MA50 | 0.88▼ | 0.89▼ | 0.89▼ | 0.96▼ | 1.26▼ |
MA100 | 0.91▼ | 0.93▼ | 0.93▼ | 1.07▼ | 2.40▼ |
MA200 | 0.94▼ | 0.96▼ | 1.03▼ | 1.23▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▲ | 0.002▲ | 0.002▲ | 0.004▲ | 0.004▲ |
RSI | 47.498▼ | 47.733▼ | 47.582▼ | 43.533▼ | 36.601▼ |
STOCH | 23.910 | 41.052 | 42.039 | 68.461 | 27.399 |
WILL %R | -71.560 | -67.944 | -67.944 | -47.647 | -76.579▼ |
CCI | -30.785 | -22.261 | -33.747 | 3.619 | -116.222▼ |
Monday, June 30, 2025 06:59 AM
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...
|
Sunday, June 29, 2025 06:13 AM
While CONMED Corporation might not have the largest market cap around , it received a lot of attention from a substantial price movement on the NYSE over the last few months, incr ...
|
Friday, June 27, 2025 09:21 AM
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
27/06/25 | 0.90 | 0.90 | 0.8512 | 0.889 | 56,826 |
26/06/25 | 0.8729 | 0.8999 | 0.8729 | 0.8816 | 20,602 |
25/06/25 | 0.851 | 0.9328 | 0.851 | 0.8999 | 84,641 |
24/06/25 | 0.8633 | 0.899 | 0.8452 | 0.8986 | 85,390 |
23/06/25 | 0.875 | 0.89 | 0.8301 | 0.89 | 57,383 |
20/06/25 | 0.89 | 0.89 | 0.85 | 0.8865 | 39,497 |
18/06/25 | 0.83 | 0.88 | 0.83 | 0.86 | 12,986 |
17/06/25 | 0.87 | 0.8718 | 0.8038 | 0.842 | 39,030 |
16/06/25 | 0.85 | 0.87 | 0.83 | 0.87 | 45,144 |
13/06/25 | 0.851 | 0.899 | 0.80 | 0.859 | 134,223 |
|
|
||||
|
|
||||
|
|